Studio di fase 2 randomizzato, in cieco, controllato con placebo, su INBRX-109 nel condrosarcoma convenzionale non resecabile o metastatico

Title

Code

PH2 INBRX- 109 SA CS

Type

Sperimentale con farmaco

Start Year

2023

Status

In Corso

Principal Investigator

051-6366101

emanuela.palmerini@ior.it

Palmerini Emanuela, MD

Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies

Operational unit that carry out the study

complex unit

Osteoncologia, Sarcomi dell'osso e dei tessuti molli, e Terapie Innovative

Director

Ibrahim Toni, BSc, MSc, MD, PhD

Go to the details >>

Documents and Videos attachament

Attachment

Nulla osta alla conduzione dello studio sperimentale prot. PH2 INBRX-109 SA CS

Friday 24 February 2023, 14:44

PG0003225_2023_Stampa_unica.pdf

You might also be interested in

Clinical Trial

A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors

Clinical Trial

Phase study 1/2 to evaluate palbociclib (IBRANCE®) in combination with irinotecan and temozolomide or in combination with topotecan and cyclophosphamide in pediatric patients with recurrent orrefractory solid tumors

IRCCS

ISTITUTO ORTOPEDICO RIZZOLI

Studio di fase 2 randomizzato, in cieco, controllato con placebo, su INBRX-109 nel condrosarcoma convenzionale non resecabile o metastatico

Principal Investigator

Operational unit that carry out the study

Documents and Videos attachament

You might also be interested in

Sito Web Istituto Ortopedico Rizzoli

Studio di fase 2 randomizzato, in cieco, controllato con placebo, su INBRX-109 nel condrosarcoma convenzionale non resecabile o metastatico

Principal Investigator

Operational unit that carry out the study

Documents and Videos attachament

You might also be interested in